Beilu Pharmaceutical (300016.SZ) obtains the registration certificate for pioglitazone metformin tablet drug.

Wisdom Finance APP News, Beilu Pharmaceutical (300016.SZ) announced that the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of Pioglitazone Metformin Hydrochloride Tablets (15mg/500mg). This product is suitable for type 2 diabetes patients who are currently using pioglitazone hydrochloride and metformin hydrochloride in combination therapy on the basis of diet control and exercise, or for type 2 diabetes patients whose blood sugar control is inadequate after using metformin hydrochloride alone.